Tag: MedAlliance

MedAlliance, a Pioneering Medical Device Startup, acquired by Cordis of USA in a Landmark USD 1.135 Billion Deal

MUMBAI, India, Oct. 5, 2023 /PRNewswire/ — MedAlliance, the visionary Swiss-based medical technology company, is delighted to announce the successful acquisition by Cordis, a transaction valued at USD 1.135 billion (Rs. ~ 10,000 Crores). This union represents a remarkable milestone in the realm of medical […]

MedAlliance announces the completion of enrollment in SAVE Trial with SELUTION SLR for Treatment of AV Fistulas in Renal Dialysis Patients

GENEVA, Aug. 15, 2023 /PRNewswire/ —  MedAlliance has announced completion of patient enrollment in the  SAVE Clinical Trial with the SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of failed AVF (arteriovenous fistulas) in renal dialysis patients. SELUTION SLR is a […]

MedAlliance leads US Sirolimus DEB race: First US Patient enrolled into SELUTION SLR Coronary Sirolimus DEB Study

GENEVA, Jan. 25, 2023 /PRNewswire/ — The first US patient has been enrolled at MedStar Washington Hospital Center in the SELUTION4ISR study evaluating SELUTION SLR™ to support FDA approval. This milestone follows Investigational Device Exemption (IDE) approval in the US in October 2022. SELUTION […]

MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval

GENEVA, Oct. 25, 2022 /PRNewswire/ — Following our communication last  week “MedAlliance to be acquired by Cordis”, MedAlliance is pleased to make the following announcement: SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device Exemption (IDE) approval to initiate its coronary pivotal […]

Cordis Announces Acquisition of MedAlliance, Positioning Itself for Market Leadership in Drug-Eluting Balloon Technology

MIAMI LAKES, Fla., Oct. 18, 2022 /PRNewswire/ — Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technologies, today announced its acquisition, subject to customary closing conditions including regulatory approvals, of MedAlliance, a Switzerland-based company at the forefront of transformative […]